Entera Bio Q1 net loss $3.8M ($0.13/shr); cash $20.1M, expects funding into Q4 2022

Entera Bio Ltd.

2023-Q1 EPS reported $0.13 revenue$68,000

Revenue $68K from Amgen R&D services, down from $157K YoY; operating expenses $3.8M vs $2.4M.
Cash $20.1M at March 31, 2022 (vs $24.9M Dec 31); expects to fund operations into Q4 2022.
EB613 (oral PTH for osteoporosis): FDA completed CMC review; Phase 3 trial design underway.
Market study: >15M U.S. osteoporosis patients, 75% untreated; clinicians favor oral anabolic.
EB612 hypoparathyroidism: orphan drug status; working on improved formulation for next trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.